CTOs on the Move

EMD Electronics

www.emdgroup.com

 
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials.
  • Number of Employees: 10K-50K
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

RxElite (Main)

RxElite (Main) is a Meridian, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CoreLab Partners

CoreLab Partners is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Teligent

Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Called TICO, our strategy is focused on developing and selling pharmaceutical products in the Topical, Injectable, Complex and Ophthalmic markets. Based in Buena, New Jersey, we have approximately 200 employees working at our 33,000 square-foot manufacturing and R&D complex, as well as in our Canada and Estonia operations. We are currently expanding our New Jersey site to include a sterile injectable, isolator-based manufacturing suite and an expanded footprint for the production of our topical products. There are three pillars that shape our company. First, we are driven by impactful science. Second, we accept no middle ground when it comes to product quality. Finally, we believe in fostering a career of craftsmanship, where our people can become experts in their trade. The spirit of our culture is to work hard, and be nice to people.

Lyra Therapeutics

Creating precisely tuned medicines so patients can breathe freely, we are pioneering a new therapeutic approach to treat debilitating ear, nose and throat diseases that impact the lives of millions of people. Lyra Therapeutics is a clinical-stage company pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people. Our goal is to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients. Lyra`s transmucosal therapeutic system, now being evaluated in a clinical study, directly targets tissues that are difficult or impossible to access with existing therapies. Building on expertise in materials science, drug development and formulation, the Lyra team has developed a proprietary platform that enables sustained, local delivery of medications over an extended period of time. Based on clinical results, this new therapeutic approach has the potential to provide significantly improved patient outcomes beyond the limited treatment and surgical options currently available for ENT diseases. Headquartered in the Boston area, Lyra Therapeutics was founded by George Whitesides and Robert Langer, academic luminaries in the fields of chemistry, materials science and biotechnology, and is backed by leading life science investors.